MicroRNAs as therapeutic targets in cardiovascular disease

The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into preclinical and clinical testing. In this Review, we summarize the current state of microRNAs as therapeutic targets in the cardiovascular system. We report recent advances in the identification and characterization of microRNAs, their manipulation and clinical translation, and discuss challenges and perspectives toward clinical application.

Automated summary

The discovery of microRNAs and their role in cardiovascular diseases has sparked interest in using microRNAs as drug targets. MicroRNA-based drugs have made significant progress in preclinical and clinical testing for cardiovascular diseases, showing great potential in treatment.